<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>タイトル</td>
<td>Taking down the heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells</td>
</tr>
<tr>
<td>著者</td>
<td>杉山 綾</td>
</tr>
<tr>
<td>引用</td>
<td>Issue Date: 2015-03-24</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10129/5608">http://hdl.handle.net/10129/5608</a></td>
</tr>
<tr>
<td>权利</td>
<td>Text version: ETD</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://repository.ul.hirosaki-u.ac.jp/dspace/">http://repository.ul.hirosaki-u.ac.jp/dspace/</a></td>
</tr>
</tbody>
</table>
Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells

(AtT-20 細胞における Hsp90 阻害による ACTH 産生及び細胞増殖の抑制作用)
Abstract

Purpose
Cushing's disease is primarily caused by adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. If excision of the tumor from the pituitary, which is the primary treatment for Cushing's disease, is unsuccessful, further medical therapy is needed to treat the resultant hypercortisolism. Some of the drugs used to treat this condition have shown potential therapeutic benefits, but a more effective treatment should be explored for the treatment of Cushing's disease. In the present study, we determined the effect of heat shock protein 90 (Hsp90) inhibitors on ACTH production and cell proliferation of AtT-20 corticotroph tumor cells.

Methods
AtT-20 pituitary corticotroph tumor cells were cultured. The expression levels of mouse proopiomelanocortin (POMC) and pituitary tumor transforming gene 1 (PTTG1) mRNA were evaluated using quantitative real-time PCR. Cellular DNA content was analyzed with fluorescence-activated cell sorting (FACS) analysis. The protein levels were determined by Western blot analysis.

Results
Both 17-allylamino-17-demethoxygeldanamycin (17-AAG) and CCT018159 decreased POMC mRNA levels in AtT-20 cells and ACTH levels in the culture medium of these cells, suggesting that both drugs suppress ACTH synthesis and secretion in corticotroph tumor cells. Both drugs also decreased cell proliferation and induced apoptosis. FACS analyses revealed that both agents increased the percentage of AtT-20 cells in the G2/M phase. These drugs decreased cell proliferation, presumably due to the induction of cell death and arrest of the cell cycle in AtT-20 cells. Tumor weight in mice xenografted with AtT-20 cells and treated with CCT018159 was lower than in AtT-20-xenografted control mice. CCT018159 also decreased plasma ACTH
levels, and POMC and PTTG1 mRNA levels in the tumor cells.

Conclusions

CCT018159 inhibits ACTH production and corticotroph tumor cell proliferation in vitro and in vivo.
Introduction

Cushing's disease is primarily caused by adrenocorticotropic hormone (ACTH)-producing pituitary adenomas [1, 2]. The normal cortisol feedback mechanism of the hypothalamic-pituitary-adrenal axis is disturbed, resulting in hypercortisolism that causes metabolic derangements such as diabetes mellitus, hypertension, atherosclerosis, and immune dysfunction [3]. Excision of the tumor from the pituitary is the primary treatment for Cushing's disease; however, if excision is unsuccessful, further therapy is needed to treat the resultant hypercortisolism [4, 5]. These therapies include repeat pituitary surgery, radiotherapy, or medical therapy. Various somatostatin receptor agonists have demonstrated inhibitory effects on tumor cell proliferation in pituitary tumors, including somatotroph and thyrotroph tumors. In some patients with Cushing's disease, SOM230 has shown promising effects by decreasing the levels of plasma ACTH and urinary free cortisol [6, 7]. Novel somatostatin-dopamine chimeric molecules or retinoic acid also appear to be a promising approach [8, 9]. Retinoic acid and curcumin may be developed as a novel therapeutic agents [10, 11]. However, a more effective medical therapy should be explored for the treatment of Cushing's disease.

Tumor growth is at least partially regulated by cell proliferation, cell cycle progression, and apoptosis. Pituitary tumor transforming gene 1 (PTTG1) is an oncogene that was first cloned from a rat pituitary tumor [12]. PTTG1 is overexpressed in many types of cancer from various origins [13]. PTTG1 is a hallmark of pituitary tumors [14, 15], and it facilitates cell cycle progression, increases pituitary cell proliferation, and promotes murine pituitary development [16].

Heat shock protein 90 (Hsp90) is an essential molecular chaperone involved in the folding and stabilization of client proteins that regulate the survival of cancer cells. Hsp90 inhibitors are promising targeted cancer therapeutic drugs that are now in clinical
trial. Geldanamycin, an ansamycin benzoquinone antibiotic and Hsp90 inhibitor, has shown antitumor effects in various tumor cells. Hsp90 inhibitors reportedly repress PTTG1 expression in carcinoma cells [17, 18], and they are expected to act on pituitary tumor cells. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) (IC$_{50}$ = 7.2 µM) is a less toxic and potent synthetic derivative of geldanamycin. CCT018159 (IC$_{50}$ = 3.2 µM) is a structurally dissimilar Hsp90 inhibitor; it is a cell-permeable pyrazole resorcinol compound that inhibits the ATPase activity of Hsp90. CCT018159 exhibits similar cellular properties to 17-AAG with potential advantages, such as aqueous solubility and independence from polymorphic enzymes [19]. Further, the effects of hypercortisolism may be reduced using Hsp90 inhibitors, because glucocorticoid receptors require Hsp90 for ligand binding.

In the present study, we examined the effects of Hsp90 inhibitors on ACTH production and cellular proliferation in AtT-20 corticotroph tumor cells. To elucidate further the possible effects of the Hsp90 inhibitors in vivo, we then examined, for the first time, the effects of CCT018159 on various parameters, including body weight, tumor weight, tumor PTTG1 and proopiomelanocortin (POMC) mRNA levels, and plasma ACTH and corticosterone levels, in AtT-20-xenografted mice.
Materials and Methods

Hsp90 inhibitors

17-AAG and CCT018159 were purchased from Wako Pure Chemical Industries (Osaka, Japan) and Tocris Bioscience (Ellisville, MO), respectively. Each inhibitor was dissolved in dimethyl sulfoxide (DMSO), diluted by cell culture medium, and used as concentrations between 100 nM and 10 µM.

Cell culture

AtT-20 pituitary corticotroph tumor cells were cultured in a T75 culture flask with Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 µg/mL streptomycin, and 100 U/mL penicillin at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. The cells were plated in 6-well plates at 1.5 × 10^5 cells/well for 2 days before each experiment and the medium was changed every 48 h. On day 3, to remove the effect of factors contained in FBS, the cells were washed and then starved overnight with DMEM supplemented with 0.2% bovine serum albumin prior to each experiment. At the end of each experiment, total cellular RNA or protein was collected and stored at -80°C until the relevant assay was performed.

Xenograft experiments

All animal studies were approved by the Institute for Animal Experiments, Hirosaki University School of Medicine and the Institutional Review Board of Hirosaki University School of Medicine. Male KSN/Slc nude mice at 8 weeks of age (approximate 22–24 g) were purchased from Japan SLC, Inc. (Shizuoka, Japan) and maintained in pathogen-free conditions. The mice were injected subcutaneously with AtT-20 cells (5.0 × 10^6 cells/mouse) in vehicle (200 µL) and divided randomly into 2 groups: control (vehicle only, n = 8) and CCT018159 (4 mg/mouse per day, n = 7). CCT018159,
dissolved in vehicle (DMSO and 0.9% saline), was administered subcutaneously once a
day for 14 days from 2 weeks after AtT-20 cell injection. We selected 4 mg
CCT018159/mouse per day because this dose was used previously to show its
pharmacokinetic and metabolic properties in rodents in vivo [20]. At the end of the
experiment, the mice were killed and tumor weights were measured after their
careful resection. All mice were killed from 02:00 to 03:00 PM. The tumors were used for
a quantitative real-time RT-PCR assay. Trunk blood was also collected for blood glucose
and corticosterone assays. Blood glucose levels were measured using Nipro StatStrip
XP (Nipro, Osaka, Japan) at the time of the experiment.

**RNA extraction**
The cells were incubated with medium alone (control) or medium containing
17-AAG or CCT018159 for the indicated times. To examine the dose-dependent effects
of 17-AAG or CCT018159, the cells were incubated for the indicated times with medium
alone (control) or medium containing increasing concentrations of 17-AAG or
CCT018159 (100 nM–10 µM). At the end of each experiment, total cellular RNA was
extracted using RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s protocol. Complementary DNA (cDNA) was synthesized from total RNA
(0.5 µg) using random hexamers as primers with the SuperScript First-Strand Synthesis
System for Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) (Invitrogen
Corp., Carlsbad, CA) according to the manufacturer’s instructions.

**Quantitative real-time RT-PCR**
Total cellular RNA extraction and cDNA synthesis were performed as described
previously [21, 22]. The resulting cDNA was then subjected to real-time PCR as follows.
The expression levels of mouse POMC (NM_008895.3) and PTTG1 (NM_001131054.1)
mRNA were evaluated using quantitative real-time PCR with specific sets of primers and probes (Assays-on-Demand Gene Expression Products; Applied Biosystems, Foster City, CA). β2-Microglobulin (B2MG) was used as a reference gene to standardize expression levels because B2MG mRNA levels did not change during any treatments in this study. Each reaction consisted of 1× TaqMan Universal PCR Master Mix (Applied Biosystems), 1× Assays-on-Demand Gene Expression Products (Mm00435874_m1 for mouse POMC, Mm00479224_m1 for mouse PTTG1, and Mm00437762_m1 for mouse B2MG), and 500 ng cDNA in a total volume of 25 µL with the following parameters on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems): 95°C for 10 min and then 40 cycles at 95°C for 15 s and 60°C for 1 min.

The above assays involved specific sets of primers and a TaqMan probe spanning the exon–exon junction and should not, therefore, have been affected by DNA contamination. Data were collected and recorded with ABI PRISM 7000 SDS software (Applied Biosystems) and expressed as a function of the threshold cycle (C_T). The amplification efficacies of each gene of interest and the reference gene amplimers were found to be identical when analyzed with diluted samples.

Relative quantitative gene expression was calculated by the $2^{-\Delta\Delta C_T}$ method. In brief, for each sample assayed, the $C_T$ for the reactions amplifying the gene of interest and a reference gene were determined. The $C_T$ for the gene of interest of each sample was corrected by subtracting the $C_T$ for the housekeeping gene (Untreated controls were chosen as reference samples, and the $C_T$ for all experimental samples was reduced by the average $C_T$ for the control samples). Finally, the abundance of the experimental mRNA relative to that of the control mRNA was calculated with use of the formula $2^{-\Delta\Delta C_T}$. 
**Western blot analysis**

Western blot analysis was performed to examine the protein levels of phosphorylated cyclic adenosine monophosphate response element-binding protein (pCREB)/CREB, phosphorylated extracellular signal-related kinases (pERK)/ERK, and phosphorylated Akt (pAkt)/Akt. β-actin was used as a housekeeping protein. The cells were washed twice with phosphate-buffered saline (PBS) and lysed with Laemmli sample buffer. Cell debris was pelleted by centrifugation and the supernatant was recovered. The samples (6 µg each sample) were boiled and subjected to electrophoresis on a 4–20% gradient polyacrylamide gel, and the proteins were transferred to a polyvinylidene fluoride membrane (Daiichi Kagaku, Tokyo, Japan). After blocking with Detector Block® buffer (Kirkegaard & Perry Laboratories, Gaithersburg, MD), the membrane was incubated for 1 h with each antibody (anti-pCREB [1:500 dilution]/CREB [1:500 dilution], anti-pERK [1:500 dilution]/ERK [1:500 dilution], and anti-pAkt [1:500 dilution]/Akt [1:2000 dilution] antibodies, Cell Signaling Technology, Beverly, MA; and anti-β-actin [1:1000 dilution] antibody, ab8227 Abcam, Cambridge, MA), washed with PBS containing 0.05% Tween 20, and incubated with horseradish peroxidase-labeled anti-rabbit immunoglobulin G ([1:20000 dilution], Daiichi Kagaku). The chemiluminescent substrate SuperSignal West Pico (Pierce Chemical Co., Rockford, IL) was used for detection and the membrane was exposed to BioMax film (Eastman Kodak Co., Rochester, NY).

**ACTH assay**

The cells were incubated at 37°C for 24 h with the indicated concentrations of 17-AAG or CCT018159. The media were then aspirated and the ACTH levels in the supernatants were measured using an ACTH enzyme-linked immunosorbent assay (ELISA) kit (MD Bioproducts, Zurich, Switzerland). The blood samples were centrifuged
and the ELISA kit was used to measure plasma ACTH levels. All samples from each experiment were determined in the same assay. The intra- and inter-assay coefficients of variation (CV) were 6.7% at 42.2 pg/mL and 7.1% at 42.3 pg/mL, respectively. Cross-reactivities with ACTH (1–24), ACTH (18–39), and α-melanocyte-stimulating hormone were -3.4%, -2.4%, and -1.7%, respectively.

**Cell proliferation assay**

The cells were incubated at 37°C for 48 h with the indicated concentrations of 17-AAG or CCT018159. Viable cells were measured using a Cell Counting Kit-8 (Dojin, Kumamoto, Japan). All samples from each experiment were determined in the same assay.

**Cell death detection assay**

The cells were incubated at 37°C for 24 h with the indicated concentrations of 17-AAG or CCT018159. DNA fragmentation was measured using a Cell Death Detection ELISA Kit (Roche, Penzberg, Germany), and each enrichment factor was calculated according to the manufacturer’s instructions.

**Cell cycle analysis**

AtT-20 cells were incubated for 24 h with medium alone (control) or medium containing 10 µM 17-AAG or CCT018159. The cells were collected by trypsinization, pelleted by centrifugation, and suspended in Triton X-100. The cells were treated at 37°C for 30 min with 0.5% RNase A and stained with propidium iodine (50 µg/mL). Cellular DNA content was analyzed with fluorescence-activated cell sorting (FACS) analysis and the cell cycle profiles were determined with BD FACSDiva™ software (Becton Dickinson, Franklin Lakes, NJ).
**Corticosterone assay**

The blood samples were centrifuged and a rodent corticosterone ELISA kit (Endocrine Technologies, Newark, CA) was used to measure plasma corticosterone levels. All samples from each experiment were determined in the same assay.

**Statistical analysis**

Each *in vitro* experiment was performed at least 3 times. Samples were provided in triplicate for each group of experiments. Each value is expressed as the mean ± standard error of the mean. For the *in vitro* studies, statistical analysis was performed with analysis of variance (ANOVA), followed by Fisher’s protected least-significant difference post hoc test. For the *in vivo* studies, statistical analysis was performed using an unpaired Student’s *t*-test. The level of statistical significance was set at *P* < 0.05.
Results

Effects of 17-AAG and CCT018159 on POMC mRNA levels

AtT-20 cells were incubated with 17-AAG or CCT018159 to determine their effects on the time- and dose-dependent changes of POMC mRNA levels. A time course study showed that 10 µM 17-AAG significantly decreased POMC mRNA levels (ANOVA; $P < 0.01$, Fig. 1A), with POMC mRNA levels falling to 43% of the control value within 24 h of the addition of 10 µM 17-AAG (Fig. 1A). POMC mRNA levels decreased in a dose-dependent manner (ANOVA; $P < 0.0005$), with significant effects observed from 1 to 10 µM (Fig. 1A).

A time course study showed that 10 µM CCT018159 significantly decreased POMC mRNA levels (ANOVA; $P < 0.05$, Fig. 1B), with POMC mRNA levels falling to 72% of the control value within 6 h of the addition of 10 µM CCT018159 (Fig. 1B). POMC mRNA levels decreased in a dose-dependent manner (ANOVA; $P < 0.01$), with significant effects observed at 10 µM (Fig. 1B).

Effects of 17-AAG and CCT018159 on ACTH levels

ACTH levels in the medium also decreased in a dose-dependent manner (ANOVA; $P < 0.005$ [17-AAG] or $P < 0.05$ [CCT018159]), with significant effects observed from 1 to 10 µM 17-AAG (Fig. 2A) or at 10 µM CCT018159 (Fig. 2B).

Effects of 17-AAG and CCT018159 on PTTG1 mRNA levels

A time course study showed that 10 µM 17-AAG potently decreased PTTG1 mRNA levels (ANOVA; $P < 0.005$, Fig. 3A), with PTTG1 mRNA levels falling to 23% of the control value within 24 h of the addition of 10 µM 17-AAG (Fig. 3A). PTTG1 mRNA levels decreased in a dose-dependent manner (ANOVA; $P < 0.005$), with significant effects observed at 10 µM (Fig. 3A).
A time course study showed that 10 µM CCT018159 significantly decreased PTTG1 mRNA levels (ANOVA; \( P < 0.005 \), Fig. 3B), with PTTG1 mRNA levels falling to 57% of the control value within 6 h of the addition of 10 µM CCT018159 (Fig. 3B). PTTG1 mRNA levels decreased in a dose-dependent manner (ANOVA; \( P < 0.05 \)), with significant effects observed at 10 µM (Fig. 3B).

**Time-dependent changes in 17-AAG- and CCT018159-induced CREB, ERK, and Akt phosphorylation**

AtT-20 cells were incubated with 10 µM 17-AAG or CCT018159 to determine their effects on CREB, ERK, and Akt phosphorylation. A time course study showed that 17-AAG decreased both CREB and ERK phosphorylation from 5 min to 6 h, while it increased Akt phosphorylation from 5 to 30 min in AtT-20 cells (Fig. 4A). CCT018159 also decreased both CREB and ERK phosphorylation from 5 min to 6 h, while it increased Akt phosphorylation from 30 min to 2 h in AtT-20 cells (Fig. 4B).

**Effects of 17-AAG and CCT018159 on cell proliferation**

AtT-20 cells were incubated with 17-AAG or CCT018159 to determine their effects on the dose-dependent changes in cell proliferation. The study showed that 10 µM 17-AAG (Fig. 5A) or 10 µM CCT018159 (Fig. 5B) significantly decreased cell proliferation (ANOVA; \( P < 0.0001 \) [17-AAG] or \( P < 0.001 \) [CCT018159]).

**Effects of 17-AAG and CCT018159 on cell death**

To examine whether 17-AAG and CCT018159 induced cell death, cytoplasmic histone-associated DNA fragmentation was determined. DNA fragmentation increased in a dose-dependent manner (ANOVA; \( P < 0.0001 \) [17-AAG] or \( P < 0.0001 \) [CCT018159]), with significant effects observed from 100 nM to 10 µM 17-AAG (Fig. 6A).
or 10 µM CCT018159 (Fig. 6B).

**Effects of 17-AAG and CCT018159 on cell cycle profiles**

Cell cycle distribution was assessed using flow cytometry. FACS analyses revealed that the percentage of cells in the S phase was decreased after incubation with 10 µM 17-AAG, and the percentage in the G2/M phase was increased after incubation with 10 µM 17-AAG or 10 µM CCT018159 (Fig. 7).

**Effects of CCT018159 on the physiology of AtT-20-xenografted mice**

AtT-20-xenografted mice produce high levels of plasma corticosterone levels and have been used as an animal model of ACTH-dependent Cushing’s disease (Taguchi et al. 2006, Fukuoka et al. 2011). AtT-20-xenografted mice were treated with CCT018159 to determine its effects on corticotroph tumor growth and function *in vivo*. In control (vehicle) mice xenografted with AtT-20 cells, body weight decreased during the study period (14 days). The decrease in body weight was significantly smaller following treatment with CCT018159 ($P < 0.01$; Fig. 8A). Tumor weight in mice treated with CCT018159 was significantly lower than in control mice ($P < 0.05$; Fig. 8B). CCT018159 also significantly decreased tumor PTTG1 and POMC mRNA levels compared with control ($P < 0.05$; Fig. 8C and 8D). Finally, CCT01859 significantly decreased plasma ACTH levels compared with control ($P < 0.05$; Fig. 8E). Plasma corticosterone levels were significantly lower following treatment with CCT018159 ($P < 0.01$; Fig. 8F). Blood glucose levels were unaltered in CCT018159-treated mice (Fig. 8G).
Discussion

Recent studies suggested that Hsp90 inhibitors are promising drugs for treating various cancers, including breast cancer, esophageal squamous cell carcinoma, and melanoma [23-25], and are now in clinical trial. In this study, we found that the Hsp90 inhibitors 17-AAG and CCT018159 decreased POMC mRNA levels in AtT-20 cells and the basal levels of ACTH in the culture medium of these cells. These results suggest that these Hsp90 inhibitors suppress the autonomic production, as well as the synthesis and release, of ACTH in corticotroph tumor cells.

Both 17-AAG and CCT018159 decreased cell proliferation in AtT-20 cells. These drugs increased DNA fragmentation in AtT-20 cells, suggesting that they induced cell death in corticotroph tumor cells. 17-AAG induces G1 arrest in prostate cancer cells [26], while it also induces G2/M arrest in lung cancer cells [27]. FACS analyses revealed that these drugs increased the percentage of AtT-20 cells in the G2/M phase, although they provoked a differential action in the S phase. G2 arrest is often associated with DNA damage; therefore, these drugs may attenuate cell cycle progression or cause cell arrest at the G2/M phase, resulting in the inhibition of cell proliferation. Decreases in cell numbers may contribute to decreases in ACTH production. Additionally, in the present study, both 17-AAG and CCT018159 gradually decreased PTTG1 mRNA levels in AtT-20 cells. Hsp90 inhibitors repress PTTG1 mRNA levels in human colon carcinoma cells [17, 18]. PTTG1 facilitates cell cycle progression and increases pituitary cell proliferation [16]. PTTG1 overexpression results in the proliferation of pituitary gonadotroph cells [15]. These findings indicate that PTTG1 may be involved in the Hsp90 inhibitor-induced suppression of cell proliferation in AtT-20 cells. Further study in the future is expected at this point.

In the present study, both 17-AAG and CCT018159 decreased CREB and ERK phosphorylation. CREB phosphorylation is increased by corticotropin-releasing factor
(CRF) via the protein kinase A (PKA) pathway in AtT-20 cells [28]. The PKA pathway has an important role in the regulation of POMC gene expression and the desensitization of CRF receptor type 1 by CRF in corticotroph cells [28, 29]. Both 17-AAG and CCT018159 decreased CREB phosphorylation in AtT-20 cells, presumably resulting in the inhibition of ACTH synthesis via the PKA pathway. ERK phosphorylation is also caused by CRF in AtT-20 cells [28]. Inhibition of the CRF-induced phosphorylation of ERK and p38 is involved in the suppression of ACTH production [30]. These decreases of CREB and ERK phosphorylation would be involved in the pathway to suppress ACTH production.

Conversely, both agents increased Akt phosphorylation. The phosphoinositide 3-kinase/Akt pathway is an intracellular signaling pathway that contributes to apoptosis or inhibition of proliferation in pituitary tumor cells [31]. Generally, this pathway is overactive in a variety of cancer cells, and 17-AAG inhibits Akt activation and expression, and shows an antiproliferative action in tumors [32]. In pituitary tumors, including thyrotroph and corticotroph tumor cells, Akt expression levels are upregulated [33, 34]. However, it is unclear what role Hsp90 inhibitor-induced Akt phosphorylation has in pituitary corticotroph tumor cells. Treatment with rapamycin, a mammalian target of rapamycin inhibitor, also reportedly increases Akt phosphorylation due to the abolition of a negative feedback loop that blunts phosphoinositide 3-kinase-mediated support for Akt activation, resulting in a reduction of sensitivity to rapamycin [35]. In this case, the addition of a somatostatin analog to rapamycin decreased Akt phosphorylation, resulting in an improvement of the antiproliferative action of this treatment in AtT-20 cells. Therefore, in addition to an Hsp90 inhibitor, adjuvant treatment with a somatostatin analog may sensitize cells to the antiproliferative effects of Hsp90 inhibitors in AtT-20 cells.

In control mice xenografted with AtT-20 cells, body weight was decreased. The
present results are consistent with those of earlier studies showing that mice with Cushing’s syndrome lose weight [36]. CCT018159 exhibits similar cellular properties to 17-AAG with potential advantages, such as aqueous solubility, for an in vivo use. Therefore, AtT-20-xenografted mice were treated with CCT018159 to determine its effects on corticotroph tumor growth and function in vivo. Tumor weight in mice treated with CCT018159 was lower than in control mice, suggesting that CCT018159 may suppress cell proliferation in vivo. In this study, CCT018159 also decreased tumor PTTG1 mRNA levels in vivo. Together, these findings indicate that PTTG1 may be partially involved in the CCT018159-induced suppression of cell proliferation in mice xenografted with AtT-20 cells.

Treatment with CCT018159 decreased tumor POMC levels, suggesting that CCT018159 suppresses ACTH synthesis in vivo. Cushing’s disease is characterized by ACTH-dependent excessive circulating glucocorticoid concentrations. Therefore, plasma ACTH and corticosterone levels have been measured in vivo [36, 37]. CCT01859 suppressed plasma ACTH levels directly via the tumor production even in vivo. Finally, plasma corticosterone levels were also decreased following treatment with CCT018159. However, the difference between ACTH levels and corticosterone levels was found in this study. Autonomous/dysregulated mild secretion of ACTH may cause excess cortisol production [38]. Otherwise, plasma corticosterone levels may be modulated via other stress factors or conditions in addition to stimulation of ACTH in vivo. Thus, this Hsp90 inhibitor should have suppressive effects on ACTH-dependent hypercortisolemia.

**Conclusion**

The present study demonstrated that 17-AAG and CCT018159 decrease POMC mRNA levels in AtT-20 cells and ACTH levels in the culture medium of these cells.
These drugs decrease cell proliferation, presumably due to the induction of cell death and cell cycle arrest in AtT-20 cells. Tumor weight in mice xenografted with AtT-20 cells and treated with CCT018159 was significantly lower than that in control mice. CCT018159 also significantly decreases plasma ACTH levels, and tumor PTTG1 and POMC mRNA levels. Thus, CCT018159 shows inhibitory effects on ACTH production and corticotroph tumor cell proliferation in vitro and in vivo.

**Conflict of interest**

None of the authors have any potential conflicts of interest associated with this research.

**Acknowledgments**

We thank the Department of Social Medicine, Hirosaki University Graduate School of Medicine, for generously providing us with FACS analysis. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
References


17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993


Res 63: 2139-2144


**Figure Legends**

**Fig. 1.** Effects of 17-AAG and CCT018159 on POMC mRNA levels in AtT-20 cells. The cells were treated in triplicate, with the average of 3 independent experiments shown (an average in triplicate was considered n = 1, n = 3). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. *P < 0.05 (compared with control [C]). (A) Time-dependent effects of 17-AAG on POMC mRNA levels (left panel): the cells were incubated with medium containing 10 µM 17-AAG. Dose-dependent effects of 17-AAG on POMC mRNA levels (right panel): the cells were incubated for 24 h with medium containing between 100 nM and 10 µM 17-AAG. (B) Time-dependent effects of CCT018159 on POMC mRNA levels (left panel): the cells were incubated with medium containing 10 µM CCT018159 (CCT). Dose-dependent effects of CCT018159 on POMC mRNA levels (right panel): the cells were incubated for 6 h with medium containing between 100 nM and 10 µM CCT018159 (CCT).

**Fig. 2.** Effects of 17-AAG and CCT018159 on ACTH levels in AtT-20 cells. The cells were treated in triplicate, with the average of 3 independent experiments shown (an average in triplicate was considered n = 1, n = 3). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. *P < 0.05 (compared with control [C]). The cells were incubated for 24 h with medium containing between 100 nM and 10 µM 17-AAG or CCT018159 (CCT).

**Fig. 3.** Effects of 17-AAG and CCT018159 on PTTG1 mRNA levels in AtT-20 cells. Effects of 17-AAG and CCT018159 on PTTG1 mRNA levels in AtT-20 cells. The cells were treated in triplicate, with the average of 3 independent experiments shown (an
average in triplicate was considered \( n = 1, n = 3 \). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. \( *P < 0.05 \) (compared with control [C]).

(A) Time-dependent effects of 17-AAG on PTTG1 mRNA levels (left panel): the cells were incubated with medium containing 10 \( \mu \)M 17-AAG. Dose-dependent effects of 17-AAG on PTTG1 mRNA levels (right panel): the cells were incubated for 24 h with medium containing between 100 nM and 10 \( \mu \)M 17-AAG.

(B) Time-dependent effects of CCT018159 on PTTG1 mRNA levels (left panel): the cells were incubated with medium containing 10 \( \mu \)M CCT018159 (CCT). Dose-dependent effects of CCT018159 on PTTG1 mRNA levels (right panel): the cells were incubated for 6 h with medium containing between 100 nM and 10 \( \mu \)M CCT018159 (CCT).

**Fig. 4.** Time-dependent changes in 17-AAG and CCT018159-induced CREB, ERK, and Akt phosphorylation in AtT-20 cells. The cells were incubated with medium containing 10 \( \mu \)M 17-AAG or CCT018159 (CCT) for the durations shown. Western blot analysis was performed to examine the protein levels of phosphorylated (p) CREB/CREB, pERK/ERK, and pAkt/Akt. Independent experiments were repeated in triplicate and a representative blot is shown.

**Fig. 5.** Effects of 17-AAG and CCT018159 on cell proliferation in AtT-20 cells. The cells were treated in triplicate, with the average of 3 independent experiments shown (an average in triplicate was considered \( n = 1, n = 3 \)). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. \( *P < 0.05 \) (compared with control [C]). The cells were incubated for 48 h with medium containing between 100 nM and 10 \( \mu \)M 17-AAG (A) or CCT018159 (CCT) (B). Viable cells were measured using a Cell Counting Kit-8.
**Fig. 6.** Effects of 17-AAG and CCT018159 on cell death in AtT-20 cells. The cells were treated in triplicate, with the average of 3 independent experiments shown (an average in triplicate was considered n = 1, n = 3). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. *P < 0.05 (compared with control [C]). The cells were incubated for 24 h with medium containing between 100 nM and 10 µM 17-AAG (A) or CCT018159 (CCT) (B). DNA fragmentation was measured using a Cell Death Detection ELISA Kit.

**Fig. 7.** Effects of 17-AAG and CCT018159 on cell cycle profiles in AtT-20 cells. Control cells were treated with medium and vehicle. A representative blot is shown in the upper panels. The cells were treated in duplicate, with the average of 3 independent experiments shown in the lower panels (an average in triplicate was considered n = 1, n = 3). Statistical analysis was performed using one-way ANOVA, followed by Fisher’s protected least-significant difference post hoc test. *P < 0.05 (compared with control [C]). The cells were incubated for 24 h with 10 µM 17-AAG, CCT018159 (CCT), or vehicle containing DMSO. Cellular DNA content was analyzed with FACS analysis and the cell cycle profiles were determined with BD FACSDiva™ software.

**Fig. 8.** Effects of CCT018159 on the physiology of AtT-20-xenografted mice. N = 8 in AtT-20-xenografted control mice treated with vehicle (C); n = 7 in AtT-20-xenografted mice treated with CCT018159 (CCT). Statistical analysis was performed using an unpaired Student’s t-test. *P < 0.05 (compared with control [C]). (A) Changes in body weight. Body weight in each mouse was determined at the end of the experiment (day 14) and compared with that at day 1. (B) Changes in tumor weight. Subcutaneous tumors were resected and weighed at the end of the experiment. (C) Changes in
PTTG1 mRNA levels in tumors. Total cellular RNA was extracted from the grafted tumor cells and the expression levels of PTTG1 mRNA were determined by real-time RT-PCR. (D) Changes in POMC mRNA levels in tumors. Total cellular RNA was extracted from the grafted tumor cells and the expression levels of POMC mRNA were determined by real-time RT-PCR. (E) Changes in plasma ACTH levels. Blood was collected at the end of the experiment and the plasma was used in the assay. (F) Changes in plasma corticosterone levels. Blood was collected at the end of the experiment and the plasma was used in the assay. (G) Changes in blood glucose levels. Blood was collected at the end of the experiment and glucose levels were measured.
Fig. 1.

(A) 17-AAG

(B) CCT

Fig. 2.

(A) 17-AAG

(B) CCT
Fig. 3.

(A) 17-AAG

(B) CCT

Fig. 4.

(A) 17-AAG

(B) CCT
Fig. 8.

(A) Body weight

(B) Tumor weight

(C) Tumor PTTG1

(D) Tumor POMC

(E) Plasma ACTH

(F) Plasma corticosterone

(G) Blood glucose